The recent discovery of new CSC surface markers and functional membrane proteins has led to suitable candidate targets such as CD13 and α3β1 for hepatocellular carcinoma (HCC) and bladder cancer, respectively [78,79]. The gene discussed is ANPEP; the disease is hepatocellular carcinoma.